The COVID-19 booster dose gap for adult beneficiaries in India has been lowered from the previously decided nine-month period to a six-month period by the Union Health Ministry. The National Technical Advisory Group on Immunization's advice served as the foundation for the decision.
After getting the nod from India's drug regulator, Gennova Biopharmaceuticals is now aiming for WHO approval for its mRNA vaccine
The United States has delivered about 2.7 million doses of COVID vaccines for children below five years to administration centres while another one million shots will reach the sites soon, the Department of Health and Human Services said on June 22.
Bharat Biotech did not immediately react to the development, but company sources reportedly said that all export orders already stand cancelled as the production has been halted.
A federal advisory committee Tuesday will vote on whether regulators should authorize a COVID-19 vaccine made by Novavax, an early beneficiary of the government’s Operation Warp Speed program.
US pharmaceutical giant Pfizer on Wednesday said it would sell its patented drugs at a not-for-profit basis to the world's poorest countries, as part of a new initiative announced at the World Economic Forum in Davos.
Drugmakers Pfizer Inc and BioNTech SE said on Monday that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.
The UN health agency’s director-general, Tedros Adhanom Ghebreyesus, told officials gathered in Geneva for opening of the WHO’s annual meeting that “declining testing and sequencing means we are blinding ourselves to the evolution of the virus.” He also noted that almost 1 billion people in lower-income countries still haven’t been vaccinated.
The companies said the vaccine was safe and well-tolerated by the children, and they plan to soon ask global regulators to authorize the shot for the age group, children for whom no vaccine is currently approved in most of the world.
"Healthcare professionals can now use Vaxzevria as a third dose booster in patients previously given a primary vaccine schedule of either Vaxzevria or an EU-approved mRNA COVID-19 vaccine."
A total of 47,761 precaution doses of COVID-19 vaccine were administered to beneficiaries aged 18-59 years till 7 pm, taking the total number of such doses given in this age-group to 16,25,744 so far, according to the ministry’s data.
Pfizer and its partner BioNTech currently make the only COVID-19 vaccine available for children of any age in the U.S. Those ages 5 to 11 receive a dose that’s one-third the amount given to everyone 12 and older.
"The vaccine meets WHO standards for protection against Covid-19 and... the benefits of the vaccine far outweigh risks," the UN health agency said in a statement.
The authorization makes everyone in the United States aged five and above eligible for booster doses of the vaccine.
Currently, Covid-19 vaccine booster doses are available to all above 18 years on the condition that the beneficiary has completed 9 months since their second shot.
The findings, published in The Lancet Infectious Disease journal, show that fourth dose mRNA booster vaccines for COVID-19 are well-tolerated in people who received Pfizer as a third dose.
Democrats have been contemplating wrapping COVID-19 aid into another emergency package for Ukraine, but it was unclear whether they will do so.
All those above the age of 18 who have completed nine months after the administration of the second dose are eligible for the precaution dose.
Covovax, the Covid-19 vaccine manufactured by the Serum Institute of India under licence from US firm Novavax, will be available at Rs 225 per dose, excluding taxes, at private healthcare facilities.
They also opined that the virus will likely circulate globally, with other prevalent respiratory viruses like influenza. It was also stated by them that this scenario almost certainly necessitates the same level of annual consideration for vaccine composition revisions.
Presently, precaution dose of Covaxin and Covishield is administered to all those aged above 18 who have completed nine months after the second dose.
Covovax is the only vaccine manufactured in India that is also sold in Europe and has an efficacy of over 90 percent, Poonawalla said while making the announcement on Twitter.
A dose of Covovax will cost Rs 900 plus GST at private vaccination centres, in addition to a hospital service charge of Rs 150.
Our specially curated package of the most interesting articles of the day will help you stay at the top of your game.
This is the Indian version of the COVID-19 vaccine, manufactured by the the US based Novavax.